METHOD FOR DETERMINING TUMOR-ASSOCIATED GLUCOSE SIDE CHAIN, METHOD FOR DIAGNOSING TUMORS, AND KIT FOR DIAGNOSING TUMORS
    6.
    发明公开
    METHOD FOR DETERMINING TUMOR-ASSOCIATED GLUCOSE SIDE CHAIN, METHOD FOR DIAGNOSING TUMORS, AND KIT FOR DIAGNOSING TUMORS 失效
    方法来确定肿瘤糖BOUND侧链方法用于肿瘤的诊断和“KIT” TO。

    公开(公告)号:EP0057236A1

    公开(公告)日:1982-08-11

    申请号:EP80901418.6

    申请日:1980-07-25

    发明人: ADACHI, Masakazu

    IPC分类号: G01N33/58

    摘要: A method for determining tumor-associated glucose side chain (TAG) in the body fluid of mammals, a method for diagnosing tumors through the determination, and a kit for diagnosis of tumors. TAG specifically existing in the body fluid of a patient suffering from a tumor is reacted with lectin to form a TAG-lectin combination entity. The amount of the combination entity or of the remaining is measured to ascertain the presence or absence of tumor cells, the degree of cell growth and the vicissitudes of the cells, thus diagnosing a tumor. The use of a kit containing vegetable lectin and, in some cases, a stabilizer and/or a preservative is particularly convenient for determination of TAG.

    摘要翻译: 一种用于在哺乳动物的体液,用于通过所述确定诊断肿瘤的方法确定的采矿肿瘤相关葡萄糖侧链(TAG)的方法,和用于肿瘤的诊断试剂盒。 TAG在来自肿瘤的患者的体液特别现有与凝集素反应,以形成TAG - 凝集素结合的实体。 剩余测量的组合或实体的量,以确定肿瘤细胞中,细胞生长程度和细胞的变迁的存在或不存在,从而诊断肿瘤。 使用的试剂盒含有植物凝集素,并且在一些情况下,稳定剂和/或防腐剂是测定TAG的特别方便。

    IMMUNE TOLERANCE INDUCERS
    7.
    发明公开
    IMMUNE TOLERANCE INDUCERS 失效
    INDUKTORENFÜRIMMUNTOLERANZ

    公开(公告)号:EP0972519A1

    公开(公告)日:2000-01-19

    申请号:EP98905773.2

    申请日:1998-03-04

    IPC分类号: A61K35/28 A61K35/14

    摘要: This invention provides a novel immunotolerance inducer which is effective in inducing immunological tolerance without involving any remarkable invasive procedure, thus ensuring the maintenance of a transplanted organ without administration of an immunosuppressant drug. This immunotolerance inducer is either a dual-system inducer comprising a first pharmaceutical composition for portal administration which comprises an effective amount of a tolerogen containing hematopoietic stem cells, hematopoietic progenitor cells, mature lymphocytes or a mixture thereof as the active component and a second pharmaceutical composition for intravenous administration which comprises an effective amount of the above-mentioned tolerogen as the active component or a single-system immunotolerance inducer which comprises an effective amount of a tolerogen containing hematopoietic stem cells, hematopoietic progenitor cells or a mixture thereof as an active component, said single-system immunotolerance inducer being administered in association with radiation.

    摘要翻译: 本发明提供了一种新颖的免疫耐受诱导剂,其有效诱导免疫耐受而不涉及任何明显的侵入性过程,从而确保维持移植的器官而不施用免疫抑制剂药物。 该免疫耐受诱导剂是包含用于门静脉给药的第一药物组合物的双系统诱导剂,其包含有效量的含有造血干细胞的耐受原体,造血祖细胞,成熟淋巴细胞或其混合物作为活性成分和第二药物组合物 用于静脉内给药,其包含有效量的作为活性成分的上述耐受原或单系免疫耐受诱导剂,其包含有效量的含有造血干细胞的致敏原,造血祖细胞或其混合物作为活性成分, 所述单系统免疫耐受诱导剂与辐射相关联地施用。